HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.
http://www.news-medical.net/news/20130301/Urea-cycle-disorder-patient-successfully-treated-by-Promethera(R)-HepaStem-in-Phase-III-trial-in-France.aspx
http://www.news-medical.net/news/20130301/Urea-cycle-disorder-patient-successfully-treated-by-Promethera(R)-HepaStem-in-Phase-III-trial-in-France.aspx
No comments:
Post a Comment